Published in Cancer Weekly, February 8th, 2005
"According to recent research from Germany, "Natural killer (NK) cells are thought to be of benefit in HLA-mismatched hematopoietic transplantation (H-SCT). Therefore, we developed a protocol for clinical-use expansion of highly enriched and IL-2-stimulated NK cells.
"Purification of unstimulated leukaphereses by a 2-step T cell depletion with a final CD56 enrichment procedure leads to a mean purity of 95% CD56+CD3- NK cells with a 4- to 5-log depletion of T cells."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.